Lin BioScience, Inc. (TPEX:6696)
Taiwan
· Delayed Price · Currency is TWD 416.50
+12.00 (2.97%)
At close: Dec 5, 2025
Lin BioScience Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Selling, General & Admin | 679.39 | 356.55 | 242.75 | 124.26 | 93.52 | 51.99 | Upgrade
|
| Research & Development | 1,304 | 1,101 | 854.07 | 320.87 | 244.76 | 145.01 | Upgrade
|
| Operating Expenses | 1,983 | 1,458 | 1,097 | 445.13 | 338.28 | 196.99 | Upgrade
|
| Operating Income | -1,983 | -1,458 | -1,097 | -445.13 | -338.28 | -196.99 | Upgrade
|
| Interest Expense | -0.96 | -1 | -1.2 | -0.88 | -0.07 | -0.25 | Upgrade
|
| Interest & Investment Income | 153.14 | 122.52 | 4.49 | 1.19 | 0.19 | 0.5 | Upgrade
|
| Currency Exchange Gain (Loss) | -12.18 | 4.89 | -1.95 | 8.87 | -0.53 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.64 | 2.94 | 4.95 | -41.93 | -151.95 | 22.09 | Upgrade
|
| EBT Excluding Unusual Items | -1,841 | -1,328 | -1,091 | -477.87 | -490.63 | -174.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.55 | - | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.22 | - | Upgrade
|
| Pretax Income | -1,832 | -1,328 | -1,091 | -477.87 | -490.41 | -174.8 | Upgrade
|
| Income Tax Expense | -69.79 | -69.6 | -29.72 | -18.44 | -9.51 | -22.95 | Upgrade
|
| Earnings From Continuing Operations | -1,763 | -1,259 | -1,061 | -459.43 | -480.9 | -151.84 | Upgrade
|
| Minority Interest in Earnings | 738.78 | 514.45 | 373.63 | 145.91 | 46.21 | - | Upgrade
|
| Net Income | -1,024 | -744.27 | -687.19 | -313.52 | -434.7 | -151.84 | Upgrade
|
| Net Income to Common | -1,024 | -744.27 | -687.19 | -313.52 | -434.7 | -151.84 | Upgrade
|
| Shares Outstanding (Basic) | 80 | 79 | 74 | 72 | 69 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 80 | 79 | 74 | 72 | 69 | 62 | Upgrade
|
| Shares Change (YoY) | 3.85% | 6.24% | 3.14% | 4.27% | 10.73% | 4.42% | Upgrade
|
| EPS (Basic) | -12.79 | -9.47 | -9.29 | -4.37 | -6.32 | -2.44 | Upgrade
|
| EPS (Diluted) | -12.79 | -9.47 | -9.29 | -4.37 | -6.32 | -2.44 | Upgrade
|
| Free Cash Flow | -1,158 | -1,025 | -1,015 | -383.4 | -291.96 | -181.18 | Upgrade
|
| Free Cash Flow Per Share | -14.47 | -13.04 | -13.72 | -5.34 | -4.24 | -2.92 | Upgrade
|
| EBITDA | -1,976 | -1,451 | -1,091 | -442.62 | -336.79 | -195.83 | Upgrade
|
| D&A For EBITDA | 7.08 | 6.56 | 5.85 | 2.51 | 1.48 | 1.17 | Upgrade
|
| EBIT | -1,983 | -1,458 | -1,097 | -445.13 | -338.28 | -196.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.